Sanofi (SNY) Set to Announce Quarterly Earnings on Thursday

Sanofi (NASDAQ:SNY) is scheduled to announce its earnings results before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of $0.99 per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). The firm had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a net margin of 12.56% and a return on equity of 27.47%. On average, analysts expect Sanofi to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $46.11 on Thursday. The company has a 50 day moving average of $47.55 and a 200 day moving average of $48.69. The stock has a market cap of $116.64 billion, a P/E ratio of 19.54, a P/E/G ratio of 1.73 and a beta of 0.61. Sanofi has a 12 month low of $42.63 and a 12 month high of $57.82. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be paid a dividend of $1.478 per share. The ex-dividend date is Thursday, May 9th. This represents a yield of 2.98%. This is a boost from Sanofi’s previous annual dividend of $1.38. Sanofi’s payout ratio is currently 62.29%.

Institutional Investors Weigh In On Sanofi

A number of hedge funds have recently made changes to their positions in SNY. Fairfield Bush & CO. bought a new stake in shares of Sanofi in the 1st quarter worth approximately $26,000. Bank of New York Mellon Corp raised its holdings in Sanofi by 31.3% during the 1st quarter. Bank of New York Mellon Corp now owns 440,646 shares of the company’s stock valued at $22,623,000 after buying an additional 105,046 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its holdings in Sanofi by 12.9% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 24,613 shares of the company’s stock valued at $1,264,000 after buying an additional 2,805 shares during the last quarter. Yousif Capital Management LLC raised its holdings in Sanofi by 45.2% during the 1st quarter. Yousif Capital Management LLC now owns 42,041 shares of the company’s stock valued at $2,158,000 after buying an additional 13,095 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Sanofi by 0.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 300,009 shares of the company’s stock valued at $15,402,000 after buying an additional 1,391 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Morgan Stanley assumed coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price for the company. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Finally, TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Sanofi currently has a consensus rating of “Hold” and a consensus target price of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.